Logo image of LEGN

LEGEND BIOTECH CORP-ADR (LEGN) Stock Fundamental Analysis

NASDAQ:LEGN - Nasdaq - US52490G1022 - ADR - Currency: USD

44.43  +0.41 (+0.93%)

Fundamental Rating

4

LEGN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. The financial health of LEGN is average, but there are quite some concerns on its profitability. LEGN is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year LEGN has reported negative net income.
LEGN had a negative operating cash flow in the past year.
In the past 5 years LEGN always reported negative net income.
LEGN had a negative operating cash flow in each of the past 5 years.
LEGN Yearly Net Income VS EBIT VS OCF VS FCFLEGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

LEGN has a Return On Assets of -13.50%. This is amongst the best in the industry. LEGN outperforms 81.83% of its industry peers.
LEGN has a Return On Equity of -21.43%. This is amongst the best in the industry. LEGN outperforms 84.35% of its industry peers.
Industry RankSector Rank
ROA -13.5%
ROE -21.43%
ROIC N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
LEGN Yearly ROA, ROE, ROICLEGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

LEGN's Gross Margin of 65.51% is amongst the best of the industry. LEGN outperforms 80.58% of its industry peers.
The Profit Margin and Operating Margin are not available for LEGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LEGN Yearly Profit, Operating, Gross MarginsLEGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

4

2. Health

2.1 Basic Checks

LEGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
LEGN has more shares outstanding than it did 1 year ago.
LEGN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for LEGN is higher compared to a year ago.
LEGN Yearly Shares OutstandingLEGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
LEGN Yearly Total Debt VS Total AssetsLEGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

LEGN has an Altman-Z score of 9.68. This indicates that LEGN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of LEGN (9.68) is better than 86.15% of its industry peers.
A Debt/Equity ratio of 0.35 indicates that LEGN is not too dependend on debt financing.
The Debt to Equity ratio of LEGN (0.35) is worse than 72.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Altman-Z 9.68
ROIC/WACCN/A
WACC9.51%
LEGN Yearly LT Debt VS Equity VS FCFLEGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

LEGN has a Current Ratio of 5.20. This indicates that LEGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.20, LEGN is in line with its industry, outperforming 54.86% of the companies in the same industry.
LEGN has a Quick Ratio of 5.07. This indicates that LEGN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of LEGN (5.07) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.2
Quick Ratio 5.07
LEGN Yearly Current Assets VS Current LiabilitesLEGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.00% over the past year.
LEGN shows a strong growth in Revenue. In the last year, the Revenue has grown by 112.46%.
The Revenue has been growing by 59.90% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-68.75%
Revenue 1Y (TTM)112.46%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%107.52%

3.2 Future

The Earnings Per Share is expected to grow by 32.04% on average over the next years. This is a very strong growth
Based on estimates for the next years, LEGN will show a very strong growth in Revenue. The Revenue will grow by 36.75% on average per year.
EPS Next Y39.73%
EPS Next 2Y61.99%
EPS Next 3Y45.97%
EPS Next 5Y32.04%
Revenue Next Year64.22%
Revenue Next 2Y59.38%
Revenue Next 3Y51%
Revenue Next 5Y36.75%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
LEGN Yearly Revenue VS EstimatesLEGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
LEGN Yearly EPS VS EstimatesLEGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

LEGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
LEGN is valuated quite expensively with a Price/Forward Earnings ratio of 74.94.
Compared to the rest of the industry, the Price/Forward Earnings ratio of LEGN indicates a rather cheap valuation: LEGN is cheaper than 88.67% of the companies listed in the same industry.
LEGN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 36.71.
Industry RankSector Rank
PE N/A
Fwd PE 74.94
LEGN Price Earnings VS Forward Price EarningsLEGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LEGN Per share dataLEGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as LEGN's earnings are expected to grow with 45.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y61.99%
EPS Next 3Y45.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LEGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEGEND BIOTECH CORP-ADR

NASDAQ:LEGN (7/23/2025, 2:07:04 PM)

44.43

+0.41 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners47.77%
Inst Owner Change-0.05%
Ins Owners0.08%
Ins Owner ChangeN/A
Market Cap8.15B
Analysts84.14
Price Target77.76 (75.02%)
Short Float %11.54%
Short Ratio5.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.01%
Min EPS beat(2)-127.98%
Max EPS beat(2)143.99%
EPS beat(4)2
Avg EPS beat(4)9.55%
Min EPS beat(4)-127.98%
Max EPS beat(4)143.99%
EPS beat(8)5
Avg EPS beat(8)2.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.48%
Min Revenue beat(2)-1.23%
Max Revenue beat(2)2.2%
Revenue beat(4)3
Avg Revenue beat(4)13.65%
Min Revenue beat(4)-1.23%
Max Revenue beat(4)44.46%
Revenue beat(8)4
Avg Revenue beat(8)4.2%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.37%
PT rev (3m)-0.3%
EPS NQ rev (1m)12.82%
EPS NQ rev (3m)30.68%
EPS NY rev (1m)8.26%
EPS NY rev (3m)20.24%
Revenue NQ rev (1m)-1.51%
Revenue NQ rev (3m)-4.52%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)-0.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 74.94
P/S 11.19
P/FCF N/A
P/OCF N/A
P/B 8.01
P/tB 8.02
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)0.59
Fwd EY1.33%
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.44
OCFYN/A
SpS3.97
BVpS5.55
TBVpS5.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.5%
ROE -21.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.51%
FCFM N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.19%
Cap/Sales 1.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.2
Quick Ratio 5.07
Altman-Z 9.68
F-Score3
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)97.56%
Cap/Depr(5y)226.91%
Cap/Sales(3y)9.76%
Cap/Sales(5y)32.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-68.75%
EPS Next Y39.73%
EPS Next 2Y61.99%
EPS Next 3Y45.97%
EPS Next 5Y32.04%
Revenue 1Y (TTM)112.46%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%107.52%
Revenue Next Year64.22%
Revenue Next 2Y59.38%
Revenue Next 3Y51%
Revenue Next 5Y36.75%
EBIT growth 1Y45.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.27%
EBIT Next 3Y58.97%
EBIT Next 5Y37.89%
FCF growth 1Y-3.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.13%
OCF growth 3YN/A
OCF growth 5YN/A